BLUE bluebird bio Inc.

139.10
-1.10  -1%
Previous Close 140.20
Open 141.20
Price To book 5.29
Market Cap 6341483454
Shares 45,589,385
Volume 495,989
Short Ratio 4.07
Av. Daily Volume 868,902

SEC filingsSee all SEC filings

  1. 8-K - Current report 171121378
  2. 8-K - Current report 171107575
  3. 8-K - Current report 171093303
  4. 8-K - Current report 171082234
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000195

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data presented at EHA June 23, 2017.
HGB-205
Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD)
Phase 3 trial to be initiated 2H 2017.
LentiGlobin - HGB-212
TDT and the β0/β0genotype
Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017 - ORR 89%. Pivotal trial to be initiated by the end of 2017.
bb2121
Relapsed/refractory multiple myeloma
Noted on December 14, 2016 that Phase 3 dosing has commenced. Early data released at EHA June 23, 2017.
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 2/3 trial initiated October 2013. Interim top-line data released June 26, 2017. Further data released October 4, 2017 - 88% free of free of major functional disabilities.
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
Updated data presented at ASH December 5, 2016.
LentiGlobin - HGB-204
β-Thalassemia
Update at ASH 2016. Further data due at ASH 2017. Exact date TBC.
LentiGlobin - HGB-206
Sickle disease

Latest News

  1. Today's Research Reports on Stocks to Watch: MannKind Corporation and Bluebird Bio
  2. bluebird bio to Present at Chardan Gene Therapy Conference
  3. bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine
  4. Why bluebird bio, Inc. Stock Gained 10% in September
  5. Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing
  6. Bluebird Bio: So Much for That Gilead Boost
  7. Here's Why Bluebird Bio (BLUE) Stock Is Falling Today
  8. Featured Company News - Bluebird Bio Declares Treatment of 1st Patient with 2nd Anti-BCMA CAR T bb21217 in CRB-402 Phase-1 Study
  9. Why Biotech and Tech Will Push Stocks Higher In 4Q
  10. Should You Be Concerned About bluebird bio Inc’s (BLUE) Risks?
  11. Bluebird Hits High On Bullish Report Highlighting Blood Drugs
  12. Why BlackBerry, AbbVie, and bluebird bio Jumped Today
  13. bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
  14. Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
  15. 3 Biotech Stocks With Major Catalysts in October
  16. Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?
  17. bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors
  18. Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade

SEC Filings

  1. 8-K - Current report 171121378
  2. 8-K - Current report 171107575
  3. 8-K - Current report 171093303
  4. 8-K - Current report 171082234
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000195
  6. 8-K - Current report 17999999
  7. 8-K - Current report 17935233
  8. 424B5 - Prospectus [Rule 424(b)(5)] 17933721
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17930064
  10. 8-K - Current report 17929923